Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 4/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592170 | 0.85 | HRH3 (0.59) | HRH3CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL7092337 | 0.79 | HRH3 (0.69) | HRH3CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL5218075 | 0.75 | HRH3 (0.50) | HRH3KCNH2HTR3ACHRM2SLC6A2 | |
| SCHEMBL5214957 | 0.75 | HRH3 (0.53) | HRH3CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL5217186 | 0.74 | HRH3 (0.49) | HRH3KCNH2HTR3ACHRM2SLC6A2 | |
| SCHEMBL5219017 | 0.73 | HRH3 (0.51) | HRH3CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL1375928 | 0.73 | HRH3 (1.00) | HRH3KCNH2HTR3ACHRM2SLC6A2 | |
| SCHEMBL1375936 | 0.73 | HRH3 (1.00) | HRH3KCNH2HTR3ACHRM2SLC6A2 | |
| SCHEMBL5214173 | 0.73 | HRH3 (0.51) | HRH3CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL240235 | 0.73 | HRH3 (0.62) | HRH3KCNH2HTR3ACHRM2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885CYP1A2 1588/4885CYP2D6 1627/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885CYP1A2 1588/4885CYP2D6 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.